Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer NA Rizvi, MD Hellmann, A Snyder, P Kvistborg, V Makarov, JJ Havel, ... Science 348 (6230), 124-128, 2015 | 8129 | 2015 |
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia, JY Han, J Molina, ... The Lancet 387 (10027), 1540-1550, 2016 | 6722 | 2016 |
Pembrolizumab for the treatment of non–small-cell lung cancer EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder, ... New England Journal of Medicine 372 (21), 2018-2028, 2015 | 6486 | 2015 |
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer L Gandhi, D Rodríguez-Abreu, S Gadgeel, E Esteban, E Felip, ... New England journal of medicine 378 (22), 2078-2092, 2018 | 5774 | 2018 |
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs MG Kris, BE Johnson, LD Berry, DJ Kwiatkowski, AJ Iafrate, II Wistuba, ... Jama 311 (19), 1998-2006, 2014 | 1795 | 2014 |
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy … EB Garon, TE Ciuleanu, O Arrieta, K Prabhash, KN Syrigos, T Goksel, ... The Lancet 384 (9944), 665-673, 2014 | 1405 | 2014 |
Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study EB Garon, MD Hellmann, NA Rizvi, E Carcereny, NB Leighl, MJ Ahn, ... Journal of Clinical Oncology 37 (28), 2518-2527, 2019 | 1043 | 2019 |
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial N Shaverdian, AE Lisberg, K Bornazyan, D Veruttipong, JW Goldman, ... The lancet oncology 18 (7), 895-903, 2017 | 1026 | 2017 |
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy D Chowell, LGT Morris, CM Grigg, JK Weber, RM Samstein, V Makarov, ... Science 359 (6375), 582-587, 2018 | 1020 | 2018 |
Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer S Gadgeel, D Rodríguez-Abreu, G Speranza, E Esteban, E Felip, ... Journal of clinical oncology 38 (14), 1505-1517, 2020 | 928 | 2020 |
Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer LV Sequist, JC Soria, JW Goldman, HA Wakelee, SM Gadgeel, A Varga, ... New England Journal of Medicine 372 (18), 1700-1709, 2015 | 823 | 2015 |
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer J Wolf, T Seto, JY Han, N Reguart, EB Garon, HJM Groen, DSW Tan, ... New England Journal of Medicine 383 (10), 944-957, 2020 | 743 | 2020 |
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer CM Rudin, CL Hann, EB Garon, M Ribeiro de Oliveira, PD Bonomi, ... Clinical Cancer Research 18 (11), 3163-3169, 2012 | 605 | 2012 |
Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized clinical trial NA Rizvi, BC Cho, N Reinmuth, KH Lee, A Luft, MJ Ahn, ... JAMA oncology 6 (5), 661-674, 2020 | 531 | 2020 |
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix, L Paz-Ares, CH Chiu, ... The Lancet Oncology 20 (12), 1655-1669, 2019 | 527 | 2019 |
A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC A Lisberg, A Cummings, JW Goldman, K Bornazyan, N Reese, T Wang, ... Journal of Thoracic Oncology 13 (8), 1138-1145, 2018 | 516 | 2018 |
Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC PC Tumeh, MD Hellmann, O Hamid, KK Tsai, KL Loo, MA Gubens, ... Cancer immunology research 5 (5), 417-424, 2017 | 466 | 2017 |
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin … JD Patel, MA Socinski, EB Garon, CH Reynolds, DR Spigel, MR Olsen, ... Journal of Clinical Oncology 31 (34), 4349-4357, 2013 | 426 | 2013 |
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). MG Kris, BE Johnson, DJ Kwiatkowski, AJ Iafrate, II Wistuba, SL Aronson, ... Journal of Clinical Oncology 29 (18_suppl), CRA7506-CRA7506, 2011 | 391 | 2011 |
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 D Rodríguez-Abreu, SF Powell, MJ Hochmair, S Gadgeel, E Esteban, ... Annals of Oncology 32 (7), 881-895, 2021 | 343 | 2021 |